Central nervous system tumors

被引:218
作者
Buckner, Jan C.
Brown, Paul D.
O'Neill, Brian P.
Meyer, Fredric B.
Wetmore, Cynthia J.
Uhm, Joon H.
机构
[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA
[5] Mayo Clin, Div Pediat Hematol Oncol, Rochester, MN 55905 USA
关键词
D O I
10.4065/82.10.1271
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Central nervous system tumors are relatively common in the United States, with more than 40,000 cases annually. Although more than half of these tumors are benign, they can cause substantial morbidity. Malignant primary brain tumors are the leading cause of death from solid tumors in children and the third leading cause of death from cancer in adolescents and adults aged 15 to 34 years. Common presenting symptoms include headache, seizures, and altered mental status. Whereas magnetic resonance imaging helps define the anatomic extent of tumor, biopsy is often required to confirm the diagnosis. Treatment depends on the histologic diagnosis. Benign tumors are usually curable with surgical resection or radiation therapy including stereotactic radiation; however, most patients with malignant brain tumors benefit from chemotherapy either at the time of initial diagnosis or at tumor recurrence. Metastases to the brain remain a frequent and morbid complication of solid tumors but are frequently controlled with surgery or radiation therapy. Unfortunately, the mortality rate from malignant brain tumors remains high, despite initial disease control. This article provides an overview of current diagnostic and treatment approaches for patients with primary and metastatic brain tumors.
引用
收藏
页码:1271 / 1286
页数:16
相关论文
共 54 条
[1]  
Afra D, 2002, LANCET, V359, P1011
[2]   Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial [J].
Andrews, DW ;
Scott, CB ;
Sperduto, PW ;
Flanders, AE ;
Gaspar, LE ;
Schell, MC ;
Werner-Wasik, M ;
Demas, W ;
Ryu, J ;
Bahary, JP ;
Souhami, L ;
Rotman, M ;
Mehta, MP ;
Curran, WJ .
LANCET, 2004, 363 (9422) :1665-1672
[3]   Phase II Randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases [J].
Antonadou, D ;
Paraskevaidis, M ;
Sarris, G ;
Coliarakis, N ;
Economou, I ;
Karageorgis, P ;
Throuvalas, N .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3644-3650
[4]   Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07 [J].
Batchelor, T ;
Carson, K ;
O'Neill, A ;
Grossman, SA ;
Alavi, J ;
New, P ;
Hochberg, F ;
Priet, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :1044-1049
[5]   Surgery versus radiosurgery in the treatment of brain metastasis [J].
Bindal, AK ;
Bindal, RK ;
Hess, KR ;
Shiu, A ;
Hassenbusch, SJ ;
Shi, WM ;
Sawaya, R .
JOURNAL OF NEUROSURGERY, 1996, 84 (05) :748-754
[6]   Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas [J].
Brada, M ;
Viviers, L ;
Abson, C ;
Hines, F ;
Britton, J ;
Ashley, S ;
Sardell, S ;
Traish, D ;
Gonsalves, A ;
Wilkins, P ;
Westbury, C .
ANNALS OF ONCOLOGY, 2003, 14 (12) :1715-1721
[7]   Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities [J].
Buckner, JC ;
Gesme, D ;
O'Fallon, JR ;
Hammock, JE ;
Stafford, S ;
Brown, PD ;
Hawkins, R ;
Scheithauer, BW ;
Erickson, BJ ;
Levitt, R ;
Shaw, EG ;
Jenkins, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :251-255
[8]   Factors influencing survival in high-grade gliomas [J].
Buckner, JC .
SEMINARS IN ONCOLOGY, 2003, 30 (06) :10-14
[9]   CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA [J].
CAIRNCROSS, G ;
MACDONALD, D ;
LUDWIN, S ;
LEE, D ;
CASCINO, T ;
BUCKNER, J ;
FULTON, D ;
DROPCHO, E ;
STEWART, D ;
SCHOLD, C ;
WAINMAN, N ;
EISENHAUER, E .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2013-2021
[10]   Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 [J].
Cairncross, Gregory ;
Berkey, Brian ;
Shaw, Edward ;
Jenkins, Robert ;
Scheithauer, Bernd ;
Brachman, David ;
Buckner, Jan ;
Fink, Karen ;
Souhami, Luis ;
Laperierre, Normand ;
Mehta, Minesh ;
Curran, Walter .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2707-2714